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ABSTRACT 
 
Bleomycin is a cytotoxic glycopeptide derived from Streptomyces verticillus and is used in ABVD (Adriamy-
cin, Bleomycin, Vinblastine, Dacarbazine) chemotherapy regimen. Bleomycin is effective against several hu-
man cancers particularly lymphomas, testicular and ovarian germ cell tumors and squamous cell carcinoma. 
Pulmonary toxicity and skin toxicity are the major toxicities of bleomycin. The various dermatological ad-
verse effects of bleomycin include flagellate dermatitis, erythema, hyperpigmentation, hyperkeratosis, 
palmoplantar desquamation, Raynaud’s phenomenon. The development of rash is independent of dose and 
route of administration. This is a case of 68 years male patient diagnosed with Hodgkin’s lymphoma who 
de-veloped rashes after receiving bleomycin based chemotherapy. The patient responded well to the anti-
hista-mines, aloe Vera-calamine lotion and bleomycin was withheld from the subsequent chemotherapy cy-
cles. 
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INTRODUCTION  
Hodgkin’s disease is a B-cell lymphoid malignancy. It 
was first described by Hodgkin in 1832[1]. It is esti-
mated to account for about 10% of cases of newly di-
agnosed lymphomas. It is most commonly diagnosed 
in the 20-34 years age group, accounting for 31% of 
new cases but can be seen across the age spectrum 
from adolescents to the elderly[2]. Treatment options 
have evolved over time ranging from radiation, cyto-
toxic chemotherapies, cellular therapies and most re-
cently targeted therapies. ABVD [Adriamycin, Bleo-
mycin, Vinblastine, and Dacarbazine] chemotherapy 
is the standard chemotherapeutic regimen for Hodg-
kin’s lymphoma[3].  
Bleomycin is a sulphur containing antimicrobial de-
rived from Streptomyces verticillus and is used as 
standard chemotherapy for Hodgkin’s lymphoma, 
germ cell tumors, Kaposi sarcoma and pleurodesis for 
malignant pleural effusions[4].It’s potential as an anti 
tumor drug was described by Umezawa in 
1965[5].Bleomycin exerts its cytotoxic effects by the 
generation of oxygen free radicals causing single and 
double stranded DNA breaks and eventual cell 
death[6]. The adverse effects of bleomycin are gastro-
intestinal [mucositis, anorexia, weight loss), respira-
tory (tachypnea, pneumonitis, pulmonary fibrosis), 
dermatological (erythema, cutaneous rash, vesicles, 
palmar and plantar scaling, hyperpigmentation, alo-
pecia and flagellate dermatitis) as well as general 
symptoms such as fever and malaise[7].  
Two major toxicities of bleomycin are pulmonary and 
skin toxicity. Lung toxicities are relatively common 
while skin toxicities are very uncommon[8]. Bleomy-
cin is inactivated in most tissues by an enzyme, Bleo-
mycin hydrolase which cleaves the ammonia group 
from bleomycin. This enzyme is active in all tissues 
except skin and lungs which account for these being 
the most common sites of toxicity. Skin reactions are 
the most common effects and are relatively late man-
ifestation usually developing after several cycles of 
chemotherapy has been administered and when the 
cumulative dose has reached 150-200U, although it 
can occur with any dose of bleomycin[6]. Flagellate er-
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ythema was first reported as an adverse effect of ble-
omycin use in 1970 by Moulin et al. The rash may ap-
pear following administration of bleomycin by any 
route: intravenous, intramuscular and topical. Males 
and females were found to be equally affected [9]. Flag-
ellate erythema and other skin toxicities may be un-
pleasant or unsightly and are not associated with in-
creased morbidity or mortality and usually resolves 
on the withdrawal of the drug. Treatment includes 
topical or systemic corticosteroids or oral antihista-
mines[9]. 
CASE STUDY 
A male patient of age 68 years was diagnosed with 
Hodgkin's lymphoma. There was no previous history 
of dermatological disorders or allergy. He had the 
past medical history of hypertension for which he 
was prescribed with Furosemide 40 mg. The patient 
was reformed smoker. He admitted for the 6th cycle of 
chemotherapy with ABVD (Adriamycin, Bleomycin, 
Vinblastine, and Dacarbazine) chemotherapy regi-
men. After receiving the 5 cycles of ABVD chemo reg-
imen, the patient developed rashes all over the body. 
Similar rashes appeared previously but were im-
proved spontaneously with Cetirizine tablet. Now 
new rashes developed again so the patient was 
promptly referred to the dermatologist.  
On examination it was found that the patient had a er-
ythematous, skin coloured papules and infiltrated 
plaques over face, upper limbs and lower limbs sug-
gesting a drug induced reaction. There was no muco-
sal involvement or systemic upset. With the charac-
teristic appearance of the rash coinciding with the 
use of bleomycin, a clinical diagnosis of bleomycin in-
duced rash was made. Routine laboratory investiga-
tions including liver function tests and renal function 
tests were normal. Bleomycin was withheld from the 
subsequent chemotherapy cycles and the patient was 
prescribed with Cetirizine tablet and calamine-aloe 
vera lotion.  
DISCUSSION 
Diverse cutaneous reactions to bleomycin therapy 
are common in the literature and are reported as hav-
ing an incidence of 8 to 20% in patients receiving cu-
mulative doses > 100 units [10]. There is a declining 
use of bleomycin in current practice due to its toxicity 
concerns; however, it is still widely used in Hodgkin’s 
disease, germ cell tumors and for pleurodesis. Bleo-
mycin is inactivated by a cytosolic cysteine protein-
ase enzyme bleomycin hydrolase which is widely dis-
tributed in normal tissues with the exception of skin 
and lungs, both targets of bleomycin toxicity[6]. Lin-
dae et al observed histological similarity to the find-
ings in fixed drug eruption and thus suggested that 
the absence of hydrolase leads to an accumulation of 
bleomycin[5].  
Various dermatological adverse effects of bleomycin 
reported in the literature include skin peeling, hyper-
keratosis, nail bed changes, Raynaud's phenomenon 
and palmoplantar desquamation. Flagellate rash has 
also been reported to occur in 10% of patients 
treated with bleomycin[6].  
Flagellate erythema is an unusual rash typically pre-
sents with itching. It was first reported in association 
with bleomycin administration in 1970. The develop-
ment of the rash appears to be dose independent and 
can appear following first administration. [3] Onset of 
characteristic lesions can occur anywhere from day 1 
to 9 weeks after bleomycin administration. The ma-
jority of patients initially develop generalized pruritis 
several hours to several weeks following the admin-
istration of bleomycin[10]. There is some evidence that 
bleomycin can be omitted from combination chemo-
therapy in the treatment of Hodgkin’s lymphoma 
without loss of efficacy. 
In most cases the rash resolves spontaneously. Ad-
dressing the symptom of itch is the main treatment 
measure. Treatment with antihistamines, topical and 
oral corticosteroids may be required. Severe rash re-
quires the cessation of drug but in mild cases the drug 
can be continued with regular monitoring and pre-
cautions. Lack of detoxifying enzymes for bleomycin 
in the skin makes it a vulnerable site for the adverse 
effects[9]. So the early recognition of bleomycin in-
duced rash is important to prevent further exacerba-
tions.  
CONCLUSION 
Bleomycin induced toxicity is a rare complication. 
Physicians must be aware of adverse effects induced 
by bleomycin. In mild non-progressive rash the drug 
can be continued with regular monitoring while se-
vere progressive rash requires discontinuation of 
bleomycin. Early recognition of adverse effects is im-
portant to modify chemotherapy and to avoid further 
toxicity. 
REFERENCES 
1. Vadakara, J., & Andrick, B. (2019). Current ad-
vances in Hodgkin’s lymphoma. Chronic diseases 
and translational medicine, 5(1), 15-24. 
2. Shanbhag, S., & Ambinder, R. F. (2018). Hodgkin 
lymphoma: a review and update on recent pro-
gress. CA: a cancer journal for clinicians, 68(2), 
116-132. 
3. Fyfe, A. J., & McKay, P. (2010). Toxicities associ-
ated with bleomycin. The journal of the Royal Col-
lege of Physicians of Edinburgh, 40(3), 213-215. 
4. Le, A., Farmakiotis, D., & Reagan, J. L. (2018). Pru-
ritic Rash in a Patient with Hodgkin's Lymphoma. 
Cureus, 10(4).  
5. Grynszpan, R., Niemeyer-Corbellini, J. P., Lopes, M. 
S. S., & Ramos-e-Silva, M. (2013). Bleomycin-in-
duced flagellate dermatitis. Case Reports, 2013, 
bcr2013009764.  
 M. Manju sai et al., (2020) Int. J. Res. Pharmaco. Vigi & Pharmaco. Therap., 1(1), 13-15 
© Rubatosis Publications | International Journal of Research In Pharmacovigilance and Pharmacotherapeutics 15  
6. Agrawal, C., Talwar, V., Saini, R., & Babu, P. (2017). 
Flagellate rash: An unusual complication of bleo-
mycin therapy–A case report with brief review of 
literature. Indian journal of medical and paediat-
ric oncology: official journal of Indian Society of 
Medical & Paediatric Oncology, 38(4), 548. 
7. Vuerstaek, J. D., Frank, J., & Poblete‐Gutiérrez, P. 
(2007). Bleomycin‐induced flagellate dermatitis. 
International journal of dermatology, 46, 3-5. 
8. Verma, S. P., Subbiah, A., Vishwanath, V. K., & 
Dutta, T. K. (2016). Bleomycin-induced skin tox-
icity: is it always flagellate erythema?. Case Re-
ports, 2016, bcr2014204575. 
9. Changal, K. H., Raina, H., Changal, Q. H., & Raina, M. 
(2014). Bleomycin-induced flagellate erythema: a 
rare and unique drug rash. The West Indian med-
ical journal, 63(7), 807. 
10. Lee, H. Y., Lim, K. H., Ryu, Y., & Song, S. Y. (2014). 
Bleomycin‐induced flagellate erythema: A case re‐
port and review of the literature. Oncology letters, 
8(2), 933-935. 
11. Biswas, A., Chaudhari, P. B., Sharma, P., Singh, L., 
Julka, P. K., & Sethuraman, G. (2013). Bleomycin 
induced flagellate erythema: revisiting a unique 
complication. Journal of cancer research and ther-
apeutics, 9(3), 500. 
12. Diao, D. Y., & Goodall, J. (2012). Bleomycin-in-
duced-flagellate dermatitis. CMAJ, 184(11), 1280-
1280. 
 
